6.5 in the placebo group), suggesting a higher potential for improvement (i.e., decrease of migraine days)
Buy Retatrutide 20mg (LY3437943) UK
However, it is currently classified in Group B of the AIS, which means that benefits are possible but the evidence remains insufficient or contradictory
Only the United States and New Zealand allow direct-to-consumer prescription drug advertising
In the SURMOUNT-1 phase-3 trial, tirzepatide produced dose-dependent weight loss reaching about ~21% of total body weight at the 15 mg dose, substantially more than placebo, with gastrointestinal symptoms the most common adverse events [6] [7]
To be eligible for Mounjaro for weight loss, you must have a body mass index (BMI) of 30 kg/m2 or more (obese), or of at least 27 kg/m2 (overweight) and have a risk factor or a health condition that is affected by weight